DDX11L2: A Potential Drug Target and Biomarker for Cancer (G84771)

Target Name: DDX11L2

NCBI ID: G84771

Other Name(s): DEAD/H box polypeptide 11 like 2 | DEAD/H (Asp-Glu-Ala-Asp/His) box helicase 11 like 2 | DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 like 2 | DEAD/H-box helicase 11 like 2 (pseudogene) | DEAD/H-box helicase 11 like 2 (pseudogene), transcript variant 1 | DDX11L2 variant 1

DDX11L2: A Potential Drug Target and Biomarker for Cancer

Dead/H box polypeptide 11 (DDX11L2) is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in cell signaling and has been implicated in a number of diseases, including cancer. In this article, we will discuss the potential implications of DDX11L2 as a drug target and biomarker.

Current Treatment Status

One of the major challenges in the treatment of cancer is the development of resistance to drugs, which can lead to a decline in treatment effectiveness. This is a particularly pressing issue forDDX11L2, as it has been shown to be involved in the development of drug resistance in variousancer types.

Research has shown thatDDX11L2 is involved in the regulation of the sensitivity of cancer cells to chemotherapy drugs. This is done through the inhibition of the enzyme topoisomerase II, which is responsible for the DNA replication process in cells. By inhibiting this enzyme, DDX11L2 has been shown to enhance the effectiveness of chemotherapy drugs in various cancer types.

DDX11L2 as a Potential Drug Target

The development of new drug targets is a critical step in the development of new treatments for cancer. DDX11L2 is an attractive candidate for drug targeting due to its involvement in the regulation of chemotherapy drug sensitivity.

One of the key advantages of DDX11L2 as a drug target is its ease of manipulation. This is because it is a protein that can be easily expressed and purified from various cell types and tissues. This makes it possible to study its effects in a controlled environment and to test its potential as a drug.

Another advantage of DDX11L2 is its potential to be used in combination with other drugs. This is because its effects can be enhanced when it is used in combination with certain chemotherapy drugs. This could lead to more effective treatment outcomes and reduced side effects.

DDX11L2 as a Biomarker

DDX11L2 has also been shown to be a potential biomarker for cancer. This is because its levels can be easily measured and its effects can be correlated with the progression of cancer.

One of the key benefits of using DDX11L2 as a biomarker is its ability to be used to track the effectiveness of cancer treatments. This is done by measuring the levels of DDX11L2 in the body and comparing them to the levels of the cancer before treatment. This allows researchers to see if the cancer is responding to treatment and to identify any potential drug resistance.

Another advantage of DDX11L2 as a biomarker is its potential to be used to predict the risk of cancer recurrence. This is done by measuring the levels of DDX11L2 in the body and comparing them to the levels of the cancer before treatment. This allows researchers to see if the cancer is at risk of recurrence and to identify any potential risk factors.

Conclusion

In conclusion, DDX11L2 is a protein that has been shown to be involved in the regulation of chemotherapy drug sensitivity and has the potential to be used as a drug target or biomarker in the treatment of cancer. Its ease of manipulation and potential to be used in combination with other drugs make it an attractive candidate for further study. Further research is needed to fully understand its potential as a drug target and biomarker in the treatment of cancer.

Protein Name: DEAD/H-box Helicase 11 Like 2 (pseudogene)

More Common Targets